Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $35.00

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its target price lifted by research analysts at HC Wainwright from $30.00 to $35.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 53.51% from the stock’s previous close.

CPRX has been the topic of several other reports. Bank of America reaffirmed a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 3rd. Truist Financial increased their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. Finally, Stephens began coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 target price on the stock. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $32.86.

Catalyst Pharmaceuticals Trading Up 16.7 %

Shares of NASDAQ CPRX opened at $22.80 on Friday. Catalyst Pharmaceuticals has a 12 month low of $13.12 and a 12 month high of $24.27. The firm has a fifty day simple moving average of $21.75 and a two-hundred day simple moving average of $19.88. The firm has a market capitalization of $2.72 billion, a PE ratio of 19.32, a price-to-earnings-growth ratio of 3.35 and a beta of 0.79.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the sale, the insider now directly owns 686,996 shares in the company, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the sale, the insider now owns 51,391 shares in the company, valued at approximately $1,167,603.52. The trade was a 18.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 79,500 shares of company stock valued at $1,754,140 in the last quarter. 11.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. GAMMA Investing LLC increased its holdings in Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 681 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at about $50,000. Larson Financial Group LLC grew its stake in shares of Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 2,994 shares during the period. Meeder Asset Management Inc. purchased a new position in shares of Catalyst Pharmaceuticals during the second quarter valued at approximately $70,000. Finally, Quantbot Technologies LP bought a new position in Catalyst Pharmaceuticals during the third quarter valued at approximately $151,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.